DNLI
Denali Therapeutics
$21.40
−$0.17 (−0.79%)Sep 10, 2026
Key metrics
The numbers that frame DNLI today
- Market cap
- $3.42B
- P/E (TTM)
- -6.7
- EV / FCF
- -7.9
- Gross margin
- 97.4%
- EV / Sales
- 957.8
- ROIC
- -53.6%
- Div yield
- 0%
- Debt / equity
- 0.3
- 52wk Low
- $12.58
- 52wk High
- $27.30
Growth
Revenue and earnings trend for DNLI
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about DNLI
Is Denali Therapeutics a good buy?
Hold. Denali Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Denali Therapeutics is selling at a very high price.
What is the market capitalization of DNLI?
Denali Therapeutics's market capitalization is $3.42B.
What is the P/E ratio for DNLI stock?
Denali Therapeutics's current P/E ratio is -6.7.
What is the 52-week high for DNLI stock?
The 52-week high for Denali Therapeutics is $27.30. The current close of $21.40 is 21.6% below that high.
What is the 52-week low for DNLI stock?
The 52-week low for Denali Therapeutics is $12.58. The current close of $21.40 is 70.1% above that low.
Does DNLI stock pay dividends?
Denali Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for DNLI?
Denali Therapeutics's Debt / Equity ratio is 0.28.